Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that China’s National Medical Products Administration has approved Exdensur (depemokimab) as an add-on therapy for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) whose disease is not adequately controlled by systemic corticosteroids and/or surgery. Exdensur is described as the first and only ultra-long-acting biologic in China for CRSwNP and is given twice a year alongside intranasal corticosteroids.
The approval is based on phase III ANCHOR-1 and ANCHOR-2 trials, which showed statistically significant reductions in nasal polyp size and nasal obstruction scores compared with placebo plus standard of care over 52 weeks. Across these trials, depemokimab was reported as well-tolerated with a similar rate and severity of side effects to placebo plus standard care. Exdensur already has approvals for severe asthma in multiple regions, and depemokimab is being studied in additional type 2 inflammation–driven diseases, broadening GSK’s respiratory portfolio.
GSK plc reports that, acting through BNP Paribas, it repurchased 335,000 ordinary shares of 31¼ pence each on 7 April 2026 as part of its existing share buyback programme.
The shares were bought at prices between 2,084.00p and 2,134.00p, with a volume‑weighted average price of 2,113.08p, and will be held as Treasury shares.
Since 17 February 2026, GSK has bought 17,236,521 shares under this programme. After this latest purchase, it holds 257,127,615 shares in treasury and has 4,059,056,834 shares in issue (excluding treasury), which equals 4,059,056,834 voting rights. Treasury shares represent 6.33% of total voting rights under DTR 5.5.1R.
GSK plc reports that on 2 April 2026 it repurchased 335,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,093.00p to 2,161.00p per share, with a volume‑weighted average price of 2,121.37p.
The acquired shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back 16,901,521 ordinary shares. After this transaction, it holds 256,792,615 shares in treasury and has 4,059,387,166 ordinary shares in issue excluding treasury, which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is confirmed at 6.33%.
GSK plc reports that it bought back 345,000 ordinary shares of 31¼ pence each on 01 April 2026 through BNP Paribas under its existing share buyback programme. The volume-weighted average price paid was 2,106.14p per share, within a range of 2,086.00p to 2,122.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 16,566,521 ordinary shares under this programme. After this transaction, GSK holds 256,457,615 ordinary shares in treasury and has 4,059,722,166 ordinary shares in issue, which equals the total number of voting rights.
GSK states that, in line with DTR 5.5.1R, the voting rights attributable to ordinary shares held in treasury represent 6.32 per cent. Shareholders can use the 4,059,722,166 voting rights figure as the denominator when assessing disclosure thresholds under the UK Financial Conduct Authority’s rules.
GSK plc reported that its Chief People Officer, Diana Conrad, acquired American Depositary Shares (ADS) under a GSK pension plan. She acquired 428.137 ADS at $52.0278 per ADS on 2026-03-24 and 12.186 ADS at $54.4682 per ADS on 2026-03-30 on the New York Stock Exchange.
GSK plc reported its total voting rights as of 31 March 2026. The company had 4,316,179,781 issued ordinary shares of 31 ¼ pence each, with 256,112,615 shares held in treasury. This leaves 4,060,067,166 voting rights, which shareholders can use as the denominator for disclosure threshold calculations under UK transparency rules.
GSK plc reports that, acting through BNP Paribas, it repurchased 340,000 ordinary shares of 31¼ pence each on 31 March 2026 as part of its existing share buyback programme. Prices ranged from 2,064.00p to 2,086.00p per share, with a volume-weighted average price of 2,075.26p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 16,221,521 ordinary shares. After this transaction, GSK holds 256,112,615 shares in treasury and has 4,060,067,166 ordinary shares in issue, giving a total of 4,060,067,166 voting rights. Treasury shares represent 6.31% of the company’s voting rights under DTR 5.5.1R.
GSK plc has completed a reshaping of ownership in HIV specialist ViiV Healthcare as Pfizer exits its investment and Shionogi increases its stake. Shionogi’s economic interest in ViiV Healthcare rises to 21.7%, while GSK maintains a 78.3% majority interest.
ViiV Healthcare issued new shares to Shionogi for $2.125 billion, cancelled Pfizer’s holding, and paid $1.875 billion to Pfizer and a $0.250 billion special dividend to GSK. GSK’s previously recorded Pfizer put option liability was extinguished through retained earnings at completion, with the final fair value remeasurement recognised as an adjusting item in other operating income.
GSK plc repurchased 340,000 ordinary shares on 30 March 2026 through BNP Paribas under its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 2,045.00p and 2,070.00p, with a volume-weighted average price of 2,060.19p.
The purchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 15,881,521 ordinary shares. After this transaction, it holds 255,772,615 shares in treasury and has 4,060,407,166 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, under DTR 5.5.1R, 6.30 per cent of its voting rights are attributable to ordinary shares held in treasury. The filing also provides a detailed schedule of buyback trades across the London Stock Exchange and CBOE Europe venues.
GSK plc reports that China’s National Medical Products Administration has accepted for review a new drug application for bepirovirsen to treat adults with chronic hepatitis B. The investigational antisense oligonucleotide showed statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well 1 and B-Well 2 trials.
Functional cure means hepatitis B virus DNA and hepatitis B surface antigen are undetectable in blood for at least 24 weeks after stopping all treatment, indicating immune control without medication. Current standard nucleos(t)ide analogue therapies typically achieve functional cure in only about 1% of patients.
Bepirovirsen, licensed from Ionis Pharmaceuticals, has Breakthrough Therapy designation in China, Fast Track designation in the US and SENKU designation in Japan, but is not yet approved anywhere. Chronic hepatitis B affects more than 250 million people worldwide and an estimated 75 million people in China, causing around 450,000 deaths a year in China.